title banner

OR in the News

OR in the News (selected articles)

Farladansky E, Hazan S, Maman E, Reuveni AM, Cattan A, Matot I, Cohen B: Perioperative oral pregabalin results in postoperative pain scores equivalent to those of interscalene brachial plexus block after arthroscopic rotator cuff repair: A randomized clinical trial. Arthroscopy 2022; 38: 31-37

May 28, 2022

To compare the analgesic effects of pregabalin to those of single-shot interscalene brachial plexus block (ISBPB) in adults having arthroscopic rotator cuff (RC) repair, as well as ISBPB’s effect on postoperative opioid con- sumption, patient satisfaction, and opioid-related adverse effects.
In this randomized trial, 79 adults having arthroscopic RC repair were randomized to receive perioperative oral pregabalin (Lyrica, twice daily starting the evening before surgery, for a total of 4 doses) or single-shot ISBPB (20 ml of bupivacaine 0.25%). Intra- and postoperative management was standardized. The primary outcome was median self-reported pain score (on a visual analog scale of 0 to 100) at rest during the initial 10 postoperative days. Other outcomes included pain during activity, postoperative opioid consumption, opioid-related adverse effects, quality of recovery, and pain satisfaction score.
Of 71 eligible patients, 59 were analyzed, of whom 29 received pregabalin and 30 received ISBPB. Groups were similar regarding demographic, baseline, and intraoperative variables. Median pain score at rest over the 10 postoperative days was 51 (interquartile range 26, 76) in the pregabalin group and 52 (22, 74) in the ISBPB group (difference 0.5 points; 95% confidence interval [CI] e3.2 to 6.3; P ¼ .53). Opioid consumption during the initial 10 postoperative days was also similar (difference in median 90 mg of morphine equivalents; 95% CI e32 to 177.5; P ¼ .12). No differences were found in any other outcome.
Perioperative use of pregabalin in adults undergoing arthroscopic RC repair pro- vided analgesia comparable to that of ISBPB for 10 days after surgery.
Level of Evidence: II, randomized controlled trial (high dropout rate)